News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,372 Results
Type
Article (13826)
Company Profile (101)
Press Release (252445)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88074)
Career Advice (465)
Deals (15346)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6301)
Job Trends (6203)
News (150266)
Policy (14046)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (37)
Alliances (23244)
ALS (39)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (45)
Approvals (6339)
Artificial intelligence (115)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (654)
Cardiovascular disease (74)
Career advice (409)
Career pathing (12)
CAR-T (24)
Cell therapy (92)
Cervical cancer (4)
Clinical research (30972)
Collaboration (361)
Compensation (165)
Complete response letters (17)
COVID-19 (760)
CRISPR (23)
C-suite (133)
Cystic fibrosis (39)
Data (694)
Denatured (15)
Depression (10)
Diabetes (84)
Diagnostics (1327)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (67)
Drug shortages (12)
Duchenne muscular dystrophy (39)
Earnings (32351)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37653)
Executive appointments (406)
FDA (6781)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (221)
Gene editing (41)
Generative AI (9)
Gene therapy (103)
GLP-1 (351)
Government (1304)
Grass and pollen (3)
Guidances (57)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (36)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (58)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5887)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (13)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (88)
Lymphoma (58)
Machine learning (4)
Management (16)
Manufacturing (170)
MASH (34)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9676)
Metabolic disorders (269)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (25)
Neuropsychiatric disorders (8)
Neuroscience (587)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (153)
Opinion (119)
Ovarian cancer (22)
Pain (58)
Pancreatic cancer (17)
Parkinson's disease (47)
Partnered (7)
Patents (127)
Patient recruitment (30)
Peanut (10)
People (29008)
Pharmaceutical (64)
Pharmacy benefit managers (12)
Phase I (8062)
Phase II (13105)
Phase III (11756)
Pipeline (529)
Policy (74)
Postmarket research (1401)
Preclinical (3236)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (174)
Real estate (2637)
Recruiting (17)
Regulatory (10155)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (38)
Series A (39)
Series B (15)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (36)
The Weekly (30)
Vaccines (159)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (67)
Last 7 days (330)
Last 30 days (1051)
Last 365 days (11701)
2025 (4232)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (58)
Arkansas (3)
Asia (20169)
Australia (2618)
California (1846)
Canada (953)
China (254)
Colorado (72)
Connecticut (73)
Delaware (62)
Europe (39565)
Florida (352)
Georgia (40)
Idaho (9)
Illinois (206)
India (16)
Indiana (138)
Iowa (1)
Japan (101)
Kansas (60)
Kentucky (13)
Louisiana (2)
Maine (2)
Maryland (273)
Massachusetts (1594)
Michigan (30)
Minnesota (99)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (809)
New Mexico (7)
New York (545)
North Carolina (408)
North Dakota (2)
Northern California (768)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (475)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (773)
Tennessee (36)
Texas (246)
United States (7690)
Utah (36)
Virginia (81)
Washington D.C. (32)
Washington State (127)
Wisconsin (19)
266,372 Results for "biomunex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology
Biomunex Pharmaceuticals announced the signature of an exclusive license and exploitation agreement with Institut Curie.
March 4, 2024
·
5 min read
Press Releases
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
December 3, 2024
·
8 min read
Drug Development
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
This first-in-man trial conducted by Onward Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bispecific antibody generated from Biomunex’ proprietary BiXAb® platform.
January 24, 2024
·
4 min read
Genetown
Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
Biomunex Pharmaceuticals announced today that it will participate in and present new scientific data at the American Association for Cancer Research (AACR) annual meeting, which will take place from April 14th to April 19th, 2023 at the Orange County Convention Center, Orlando, Florida.
April 12, 2023
·
2 min read
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Onward Therapeutics SA announced the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS, Paris, France, of a bispecific antibody targeting two immune checkpoints.
February 16, 2021
·
3 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Business
Biomunex Pharmaceuticals Establishes US Subsidiary
Biomunex Inc. to focus on R&D and business development activities in the US
May 28, 2019
·
3 min read
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Apellis Pharmaceuticals to Present at Upcoming May 2025 Investor Conferences
May 7, 2025
·
1 min read
Press Releases
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
May 7, 2025
·
19 min read
1 of 26,638
Next
